PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+57.5%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.47B
AUM Growth
+$4.47B
(+50%)
Cap. Flow
+$491M
Cap. Flow
% of AUM
10.98%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
116
New
21
Increased
27
Reduced
22
Closed
11
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$81.5M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
$79.6M |
| 3 |
Spyre Therapeutics
SYRE
|
$54.4M |
| 4 |
Axsome Therapeutics
AXSM
|
$44.3M |
| 5 |
Biohaven
BHVN
|
$41.7M |
Top Sells
| 1 |
argenx
ARGX
|
$74M |
| 2 |
Immunovant
IMVT
|
$62.6M |
| 3 |
Roivant Sciences
ROIV
|
$44.6M |
| 4 |
Harmony Biosciences
HRMY
|
$32.6M |
| 5 |
Relay Therapeutics
RLAY
|
$16.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CERE
1
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $465M | 10.38% | 10,965,193 +876,808 | +9% | +$37.2M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $398M | 8.89% | 28,057,456 +364,539 | +1% | +$5.17M |
|
|
LIAN
3
DELISTED
LianBio American Depositary Shares
LIAN
| $257M | 5.74% | 57,558,451 | – | – |
|
4
Arcellx
ACLX
$3.85B
| $252M | 5.63% | 4,544,809 +578,831 | +15% | +$32.1M |
|
5
Nuvalent
NUVL
$5.52B
| $215M | 4.79% | 2,917,991 +454,540 | +18% | +$33.4M |
|
|
INBX
6
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $162M | 3.61% | 4,256,104 | – | – |
|
7
Soleno Therapeutics
SLNO
$3.6B
| $124M | 2.76% | 3,074,542 | – | – |
|
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $99M | 2.21% | 2,154,110 +1,773,282 | +466% | +$81.5M |
|
|
9
Immunovant
IMVT
$2.56B
| $98.1M | 2.19% | 2,328,082 -1,486,609 | -39% | -$62.6M |
|
10
Iovance Biotherapeutics
IOVA
$807M
| $97.4M | 2.17% | 11,979,415 +16,477 | +0.1% | +$134K |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $95.1M | 2.12% | 4,024,400 -18,791 | -0.5% | -$444K |
|
|
12
Axsome Therapeutics
AXSM
$6.05B
| $82.6M | 1.84% | 1,038,019 +556,370 | +116% | +$44.3M |
|
13
Medtronic
MDT
$119B
| $80.5M | 1.8% | 976,652 +389,652 | +66% | +$32.1M |
|
|
CRGX
14
DELISTED
CARGO Therapeutics
CRGX
| $79.6M | 1.78% | +3,436,600 | New | +$79.6M |
|
15
MeiraGTx Holdings
MGTX
$587M
| $79.5M | 1.78% | 11,331,103 | – | – |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $76.9M | 1.72% | 3,866,214 -140,983 | -4% | -$2.8M |
|
|
17
Biohaven
BHVN
$1.63B
| $73.8M | 1.65% | 1,725,047 +973,227 | +129% | +$41.7M |
|
|
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
| $71.4M | 1.59% | 1,957,246 +436,830 | +29% | +$15.9M |
|
19
BridgeBio Pharma
BBIO
$9.89B
| $70.6M | 1.58% | 1,748,933 | – | – |
|
20
Vaxcyte
PCVX
$4B
| $68.4M | 1.53% | 1,088,486 -254,265 | -19% | -$16M |
|
21
Lyra Therapeutics
LYRA
$11.5M
| $66.8M | 1.49% | 12,757,562 | – | – |
|
22
Disc Medicine
IRON
$2.07B
| $59.1M | 1.32% | 1,023,045 +127,404 | +14% | +$7.36M |
|
|
23
Spyre Therapeutics
SYRE
$996M
| $56.1M | 1.25% | 2,606,679 +2,525,563 | +3,114% | +$54.4M |
|
24
Natera
NTRA
$23.1B
| $53.3M | 1.19% | 850,225 +632,047 | +290% | +$39.6M |
|
25
RAPT Therapeutics
RAPT
$188M
| $53.2M | 1.19% | 2,139,950 +219,292 | +11% | +$5.45M |
|